A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
A phase 1/2 trial of TRI-611 in non-small-cell lung cancer and small-cell lung cancer, run by TRIANA Biomedicines, Inc., now recruiting.
Overview
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC is a phase 1/2 interventional study registered as NCT07491497 by TRIANA Biomedicines, Inc., with 160 participants planned, started 2026-03-11 and due to reach its primary completion in 2029-05-31. Interventions recorded: TRI-611. Conditions listed: ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC
Phase
Phase 1/2
Sponsor
TRIANA Biomedicines, Inc.
Registry
Enrolled
160
Similar pages
not linked directly; found by shared links- TargetALK
Shares TRI-611, Triana Biomedicines, Non-small-cell lung cancer.